Novo Nordisk’s Q3 2025 earnings report showed strong demand for Wegovy, with a 15% increase in U.S. sales and a 10% rise in operating profit. Despite this, the stock fell 3.9%, marking a 45% decline for the year. The company announced FDA approval of Wegovy for MASH, expanding its market potential. Novo Nordisk is also in talks to acquire Akero Therapeutics and Omeros’ MASP-3 inhibitor, among other strategic moves in the rare disease and weight management markets. Eli Lilly, Nordisk’s competitor, challenges its dominance in the weight-loss drug market, prompting Nordisk to accelerate new drug launches and acquisitions. Discussions at the White House may lead to the sale of low-dose weight loss drugs through the proposed TrumpRx plan, which could impact the market and coverage under Medicare and Medicaid.

Read more at Yahoo Finance: GLP-1 goliath updates demand for top weight loss drug